Argenx SE ARGX
Annual
Quarterly
FY2023 · ended Dec 31, 2023 · Revenue $35.53M, +254.4% YoY · Filed Mar 19, 2026
Argenx SE (ARGX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was $679.0 million. As of Dec 31, 2025 it held $3.5 billion in cash and investments and $47.2 million in total debt.
Revenue
$35.53M
+254.4% vs prior year
Net income
$1.29B
+55.1% vs prior year
Operating cash flow
$685.19M
+928.1% vs prior year
Free cash flow
$679.03M
+903.1% vs prior year
EPS
$19.57
+53.1% vs prior year
Dividend per share
None
Shares outstanding
61.88M
+1.8% vs prior year
Net cash
$3.44B
FY 2025
Operating margin
-1196.2%
FY 2023
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ARGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Zwijnaarde
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1697862
- Former names
- argenx N.V (until Apr 21, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $35.5M | $10.0M | $497.3M |
| Operating income | $1.1B | -$21.7M | -$425.0M | -$720.3M | -$348.7M |
| Net income | $1.3B | $833.0M | -$295.1M | -$709.6M | -$408.3M |
| Diluted EPS | $19.57 | $12.78 | -$5.16 | -$13.05 | -$7.99 |
| Operating cash flow | $685.2M | -$82.7M | -$420.3M | -$862.8M | -$606.8M |
| Free cash flow | $679.0M | -$84.5M | -$421.1M | -$863.6M | -$610.4M |
| Total assets | $8.7B | $6.2B | $4.5B | $3.1B | $2.9B |
| Total liabilities | $1.4B | $704.2M | $445.0M | $320.6M | $316.1M |
| Stockholders' equity | $7.3B | $5.5B | $4.1B | $2.8B | $2.5B |
| Cash and investments | $3.5B | $1.5B | $2.0B | $800.7M | $1.3B |
| Total debt | $47.2M | $39.1M | $27.2M | $12.4M | $11.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 29, 2026 | Sep 29, 2026 |
| 6-K | Current report (foreign issuer) | Aug 27, 2026 | Aug 27, 2026 |
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Aug 17, 2026 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.